4.7 Review

Signaling pathways and therapeutic interventions in gastric cancer

Journal

Publisher

SPRINGERNATURE
DOI: 10.1038/s41392-022-01190-w

Keywords

-

Funding

  1. National Natural Science Foundation of China [U20A20379]
  2. National Key Research and Development Program of China [2018YFA0902801]
  3. 100 Top Talents Program of Sun Yat-Sen University [ZSQYBRJH0001]
  4. Guangdong Basic and Applied Basic Research Foundation [2021A1515010117]
  5. Guangdong Provincial Key Laboratory of Digestive Cancer Research [2021B1212040006]
  6. Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University

Ask authors/readers for more resources

Gastric cancer is the fifth most diagnosed cancer and the fourth leading cause of cancer-related death worldwide. Advancements in genome analysis have identified biomarkers and signaling pathways that play vital roles in gastric cancer development, progression, and treatment response. These discoveries provide a direction for improving gastric cancer diagnosis and treatment.
Gastric cancer (GC) ranks fifth in global cancer diagnosis and fourth in cancer-related death. Despite tremendous progress in diagnosis and therapeutic strategies and significant improvements in patient survival, the low malignancy stage is relatively asymptomatic and many GC cases are diagnosed at advanced stages, which leads to unsatisfactory prognosis and high recurrence rates. With the recent advances in genome analysis, biomarkers have been identified that have clinical importance for GC diagnosis, treatment, and prognosis. Modern molecular classifications have uncovered the vital roles that signaling pathways, including EGFR/HER2, p53, PI3K, immune checkpoint pathways, and cell adhesion signaling molecules, play in GC tumorigenesis, progression, metastasis, and therapeutic responsiveness. These biomarkers and molecular classifications open the way for more precise diagnoses and treatments for GC patients. Nevertheless, the relative significance, temporal activation, interaction with GC risk factors, and crosstalk between these signaling pathways in GC are not well understood. Here, we review the regulatory roles of signaling pathways in GC potential biomarkers, and therapeutic targets with an emphasis on recent discoveries. Current therapies, including signaling-based and immunotherapies exploited in the past decade, and the development of treatment for GC, particularly the challenges in developing precision medications, are discussed. These advances provide a direction for the integration of clinical, molecular, and genomic profiles to improve GC diagnosis and treatments.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available